Tessa Romero
Stock Analyst at JP Morgan
(4.34)
# 349
Out of 5,154 analysts
78
Total ratings
53.33%
Success rate
19.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $31 → $34 | $22.16 | +53.43% | 12 | Mar 4, 2026 | |
| DYN Dyne Therapeutics | Maintains: Neutral | $17 → $16 | $14.86 | +7.67% | 8 | Jan 20, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $70 → $74 | $60.41 | +22.50% | 6 | Jan 20, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $60 → $62 | $41.94 | +47.83% | 4 | Jan 9, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $20 → $25 | $27.47 | -8.99% | 8 | Jan 6, 2026 | |
| OCS Oculis Holding AG | Initiates: Overweight | $38 | $26.96 | +40.95% | 1 | Dec 19, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $47 → $15 | $9.92 | +51.21% | 8 | Nov 20, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $46 → $47 | $45.29 | +3.78% | 6 | Nov 18, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Underweight | $261 → $263 | $4.41 | +5,863.72% | 1 | Nov 18, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $33 → $34 | $27.82 | +22.21% | 11 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.02 | - | 5 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $10 | $6.85 | +45.99% | 2 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $7.66 | +396.08% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.13 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $29 | $15.75 | +84.13% | 3 | Aug 13, 2024 |
ACADIA Pharmaceuticals
Mar 4, 2026
Maintains: Overweight
Price Target: $31 → $34
Current: $22.16
Upside: +53.43%
Dyne Therapeutics
Jan 20, 2026
Maintains: Neutral
Price Target: $17 → $16
Current: $14.86
Upside: +7.67%
Cytokinetics
Jan 20, 2026
Maintains: Overweight
Price Target: $70 → $74
Current: $60.41
Upside: +22.50%
Xenon Pharmaceuticals
Jan 9, 2026
Maintains: Overweight
Price Target: $60 → $62
Current: $41.94
Upside: +47.83%
Agios Pharmaceuticals
Jan 6, 2026
Maintains: Neutral
Price Target: $20 → $25
Current: $27.47
Upside: -8.99%
Oculis Holding AG
Dec 19, 2025
Initiates: Overweight
Price Target: $38
Current: $26.96
Upside: +40.95%
Biohaven
Nov 20, 2025
Maintains: Overweight
Price Target: $47 → $15
Current: $9.92
Upside: +51.21%
Scholar Rock Holding
Nov 18, 2025
Maintains: Overweight
Price Target: $46 → $47
Current: $45.29
Upside: +3.78%
Rocket Pharmaceuticals
Nov 18, 2025
Downgrades: Underweight
Price Target: $261 → $263
Current: $4.41
Upside: +5,863.72%
Edgewise Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $27.82
Upside: +22.21%
Sep 16, 2025
Downgrades: Underweight
Price Target: n/a
Current: $3.02
Upside: -
May 30, 2025
Maintains: Overweight
Price Target: $16 → $10
Current: $6.85
Upside: +45.99%
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $7.66
Upside: +396.08%
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $9.13
Upside: -
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $15.75
Upside: +84.13%